Hofseth BioCare ASA (HBC.OL)
NOK 2.1
(0.95%)
NOK 2.1
(0.95%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 390.11 Million NOK | -5.09% |
| 2022 | 411.03 Million NOK | -1.19% |
| 2021 | 415.97 Million NOK | -9.4% |
| 2020 | 459.13 Million NOK | 56.69% |
| 2019 | 293.01 Million NOK | 55.9% |
| 2018 | 187.94 Million NOK | 2.01% |
| 2017 | 184.23 Million NOK | 15.62% |
| 2016 | 159.35 Million NOK | -17.58% |
| 2015 | 193.34 Million NOK | -11.25% |
| 2014 | 217.86 Million NOK | 6.25% |
| 2013 | 205.05 Million NOK | 31.75% |
| 2012 | 155.63 Million NOK | -1.72% |
| 2011 | 158.36 Million NOK | 67.48% |
| 2010 | 94.55 Million NOK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 390.71 Million NOK | 0.15% |
| 2024 Q2 | 385.52 Million NOK | -1.33% |
| 2023 Q3 | 401.98 Million NOK | -2.18% |
| 2023 Q4 | 390.11 Million NOK | -2.95% |
| 2023 FY | 390.11 Million NOK | -5.09% |
| 2023 Q1 | 391.26 Million NOK | -4.81% |
| 2023 Q2 | 410.95 Million NOK | 5.03% |
| 2022 Q1 | 397.91 Million NOK | -4.34% |
| 2022 FY | 411.03 Million NOK | -1.19% |
| 2022 Q4 | 411.03 Million NOK | -2.45% |
| 2022 Q3 | 421.33 Million NOK | 11.21% |
| 2022 Q2 | 378.87 Million NOK | -4.79% |
| 2021 Q2 | 458.11 Million NOK | 3.33% |
| 2021 FY | 415.97 Million NOK | -9.4% |
| 2021 Q1 | 443.33 Million NOK | -3.44% |
| 2021 Q3 | 443.34 Million NOK | -3.23% |
| 2021 Q4 | 415.97 Million NOK | -6.17% |
| 2020 Q2 | 306.87 Million NOK | 4.5% |
| 2020 Q1 | 293.66 Million NOK | 0.22% |
| 2020 FY | 459.13 Million NOK | 56.69% |
| 2020 Q3 | 293.28 Million NOK | -4.43% |
| 2020 Q4 | 459.13 Million NOK | 56.55% |
| 2019 Q3 | 330.54 Million NOK | 44.41% |
| 2019 FY | 293.01 Million NOK | 55.9% |
| 2019 Q1 | 245.09 Million NOK | 30.41% |
| 2019 Q4 | 293.01 Million NOK | -11.35% |
| 2019 Q2 | 228.89 Million NOK | -6.61% |
| 2018 Q1 | 151.7 Million NOK | -17.66% |
| 2018 FY | 187.94 Million NOK | 2.01% |
| 2018 Q4 | 187.94 Million NOK | -4.14% |
| 2018 Q2 | 151.2 Million NOK | -0.33% |
| 2018 Q3 | 196.06 Million NOK | 29.66% |
| 2017 Q2 | 142.66 Million NOK | -22.06% |
| 2017 FY | 184.23 Million NOK | 15.62% |
| 2017 Q4 | 184.23 Million NOK | 22.18% |
| 2017 Q1 | 183.04 Million NOK | 14.87% |
| 2017 Q3 | 150.79 Million NOK | 5.7% |
| 2016 Q4 | 159.35 Million NOK | -16.56% |
| 2016 FY | 159.35 Million NOK | -17.58% |
| 2016 Q1 | 164.46 Million NOK | -14.94% |
| 2016 Q2 | 158.01 Million NOK | -3.93% |
| 2016 Q3 | 190.99 Million NOK | 20.87% |
| 2015 Q1 | 213 Million NOK | -2.23% |
| 2015 FY | 193.34 Million NOK | -11.25% |
| 2015 Q4 | 193.34 Million NOK | -15.05% |
| 2015 Q3 | 227.58 Million NOK | -5.86% |
| 2015 Q2 | 241.75 Million NOK | 13.5% |
| 2014 Q2 | 226.61 Million NOK | 7.36% |
| 2014 FY | 217.86 Million NOK | 6.25% |
| 2014 Q1 | 211.08 Million NOK | 2.94% |
| 2014 Q4 | 217.86 Million NOK | -6.92% |
| 2014 Q3 | 234.07 Million NOK | 3.29% |
| 2013 Q4 | 205.05 Million NOK | 0.07% |
| 2013 Q2 | 206.25 Million NOK | -2.72% |
| 2013 Q1 | 212.03 Million NOK | 36.23% |
| 2013 FY | 205.05 Million NOK | 31.75% |
| 2013 Q3 | 204.91 Million NOK | -0.65% |
| 2012 Q3 | 178.47 Million NOK | 15.09% |
| 2012 Q1 | 147.96 Million NOK | -6.57% |
| 2012 FY | 155.63 Million NOK | -1.72% |
| 2012 Q2 | 155.06 Million NOK | 4.8% |
| 2012 Q4 | 155.63 Million NOK | -12.79% |
| 2011 Q4 | 158.36 Million NOK | 26.29% |
| 2011 Q3 | 125.4 Million NOK | 0.0% |
| 2011 FY | 158.36 Million NOK | 67.48% |
| 2010 FY | 94.55 Million NOK | 0.0% |
| 2010 Q4 | 94.55 Million NOK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Arctic Bioscience AS | 300.25 Million NOK | -29.931% |
| Aqua Bio Technology ASA | 34.42 Million NOK | -1033.095% |
| ArcticZymes Technologies ASA | 339.32 Million NOK | -14.97% |
| BerGenBio ASA | 174.33 Million NOK | -123.775% |
| PCI Biotech Holding ASA | 44.05 Million NOK | -785.628% |
| Thor Medical ASA | 330.83 Million NOK | -17.92% |
| Ultimovacs ASA | 349.03 Million NOK | -11.769% |